Qiagen NV provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide. The company was founded in 1986 and is based in Venlo, the Netherlands.
QGEN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for QGEN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Qiagen Nv ranked in the 13th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for QGEN, they are:
Qiagen Nv's effective tax rate, as measured by taxes paid relative to net income, is at 91 -- greater than 97% of US stocks with positive free cash flow.
Qiagen Nv's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.05. This coverage rate is greater than that of only 17.97% of stocks we're observing for the purpose of forecasting via discounted cash flows.
The weighted average cost of capital for the company is 10. This value is greater than 81.19% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Qiagen Nv? See A, VAR, ENDP, IDXX, and MGLN.